VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 363 EUR | -2.55% |
|
+1.40% | +0.97% |
| May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play |  |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
| Sales 2024 * | 1.38B 1.49B | Sales 2025 * | 1.48B 1.6B | Capitalization | 3.04B 3.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 139M 150M | Net income 2025 * | 155M 167M | EV / Sales 2024 * | 2.26 x |
| Net Debt 2024 * | 74.94M 80.94M | Net cash position 2025 * | 43.1M 46.55M | EV / Sales 2025 * | 2.02 x |
| P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
19.8
x | Employees | 5,459 |
| Yield 2024 * |
0.4% | Yield 2025 * |
0.45% | Free-Float | 48.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 day | -2.55% | ||
| 1 week | +1.40% | ||
| Current month | +1.40% | ||
| 1 month | +4.16% | ||
| 3 months | +6.92% | ||
| 6 months | +24.32% | ||
| Current year | +0.97% |
1 week
348.00
372.50
1 month
348.00372.50
Current year
316.50377.50
1 year
232.50377.50
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philippe Capron
BRD | Director/Board Member | 65 | 03-12-31 |
| Chairman | 59 | 97-12-31 | |
| Director/Board Member | 63 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 363 | -2.55% | 9,693 |
| 24-06-06 | 372.5 | +3.47% | 3,170 |
| 24-06-05 | 360 | +2.71% | 2,883 |
| 24-06-04 | 350.5 | -0.57% | 3,375 |
| 24-06-03 | 352.5 | -1.54% | 2,516 |
Real-time Euronext Paris, June 07, 2024 at 11:37 am EDT
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
363
EUR
Average target price
373.3
EUR
Spread / Average Target
+2.85%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.97% | 3.28B | |
| +22.21% | 9B | |
| +24.50% | 3.69B | |
| +15.20% | 1.69B | |
| -0.20% | 1.31B | |
| -26.00% | 1.23B | |
| -29.34% | 1.18B | |
| -23.11% | 1B | |
| -11.78% | 923M | |
| +1.54% | 932M |
- Stock Market
- Equities
- VIRP Stock
